Related Experiment Video
Updated: Jul 19, 2025

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
Histiocytic neoplasms: Going, going, but not quite gone
1Institute of Translational and Clinical Research, Newcastle University, Newcastle upon Tyne, UK.
None:
BRAF and MEK inhibitors have revolutionised the treatment of patients with high-risk histiocytic neoplasms but does a complete response mean that treatment can be withdrawn? Commentary on: Reiner et al. Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms. Br J Haematol 2023;203:389-394.
More Related Videos
09:43Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019